Mana.bio is an innovative startup that leverages artificial intelligence (AI) and nanotechnology to revolutionize drug delivery, particularly in the realm of gene therapy and vaccines. The company focuses on the design and optimization of lipid nanoparticle (LNP) systems, which are crucial for the effective delivery of nucleic acid therapeutics. By integrating machine learning with LNP design, Mana.bio aims to overcome traditional challenges in drug delivery, enabling precise formulations that target specific tissues outside the liver. This AI-driven approach not only accelerates the development process but also leads to the creation of novel, intellectual property-protected solutions that can foster collaborations within the biotech and pharmaceutical sectors.

The technology at Mana.bio is characterized by a robust platform that utilizes high-throughput capabilities for the synthesis of multiple LNP formulations weekly. Their automated manufacturing pipelines transform computational models into tangible products, which are then rigorously tested through high-throughput screening to assess efficacy, safety, and physicochemical properties. The results from these evaluations are systematically integrated into the AI platform, enhancing the machine learning models and refining the design of tissue-targeted LNPs. This continuous feedback loop, combined with the incorporation of publicly available data, enriches their proprietary database, further improving the predictive capabilities of their AI models and advancing the field of genetic medicine.

United States

Mana.bio is an AI based drug delivery startup, creating a platform for Lipid Nanoparticle (LNP) development for oligonucleotide therapies including mRNA-based therapeutics, vaccines and gene therapy.

Mana.bio

Company Details